Medical device firm Focal Therapeutics said a recent study found that its BioZorb surgical tissue marker facilitated more precise delivery of radiation therapy for breast cancer.
In a 51-patient study presented at last month's American Society for Radiation Oncology (ASTRO) meeting, a team led by Dr. Robert Kuske of Arizona Breast Cancer Specialists found that BioZorb use led to reduced radiation treatment volumes and smaller radiation doses.
In addition, use of the marker with oncoplastic surgery produced excellent cosmetic outcomes, according to the vendor.
